Search
-
Predicting Opportunity in Emerging Therapies
We offer guidance for navigating these complex markets, emphasizing the need for robust primary market research, expert consultation, and a deep understanding of stakeholder perceptions.
-
Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
This panel discussion hosted by the Pharmaceutical & BioScience Society will explore the evolution of these and other agents (e.g. gastric inhibitory polypeptide [GIP] receptor agonists), including clinical efficacy and safety results, HCP and consumer perspectives, market adoption, and the access, reimbursement, and intellectual property (IP) landscapes.
-
Americans say they're dining out less. Here's who's cutting back the most.
The latest data from the Ipsos Consumer Tracker reflects a downturn in spending on fast food. But where is that trend strongest — and what's the luxury that the fewest Americans are cutting back on?
-
Brand Success in the GLP-1 Era
Our roadmap for GLP-1 brand success is based on the three fundamental pillars of understanding Context, acting with Empathy, and shaping Expectations.
-
How AI, new drugs, and your DNA will help us live better for longer
What wellness — physical, mental, and otherwise — looks like matters for all of us, as individuals and as consumers. Matt Carmichael, editor of What the Future, looks at what the future could hold.
-
What anti-obesity drugs could shift in how we think about weight
We’re still in the early days of the GLP-1 revolution, but it’s already changing how patients and caregivers think about and treat obesity. WeightWatchers’ Dr. Spencer Nadolsky explains what this shift tells us about the future of wellness.
-
How new obesity medications could transform the grocery landscape
Anti-obesity medications’ influence on Americans’ personal habits and diets could have cascading effects for food and beverage retailers, according to a new Ipsos study. Ipsos’ Rhoda Schmuecking explains.
-
So Much to Lose: Changing landscape of obesity in America
Revisit our recorded webinar exploring obesity, weight loss, and the broader implications for sectors from healthcare to food and beverage.
-
Monitoring the obesity treatment revolution, in healthcare and beyond
Ipsos has launched three new syndicated studies to monitor and anticipate changes in the rapidly evolving landscape of obesity treatment.
-
[WEBINAR] So Much to Lose: Changing landscape of obesity in America
Would you take a medication that would help you lose weight? Join us on December 13 as we deep dive into the implications of new obesity treatments.